Proteotech Inc.

Cognitive Clarity Inc.

Protamed, Inc.

Joel Cummings

Alan D Snow

Thomas P Lake

Qubai Hu

Judy Cam

F Michael Hudson

Luke A Esposito

Marisa C Yadon

Manfred Weigele

Lesley Larsen

Anil M Kumar

Virginia J Sanders

Franz F Hefti

Esposito A Luke

Geoffrey Golding

Seok-Rye Choi

Ximin Li

Kelsey Hanson

Anil Kumar

Composition and methods for treating brain 'plaques' and 'tangles' in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncariaextract and an oolong tea extract.

Compositions and methods for the treatment of plaques and tangles in humans and animals

Methods of treating the formation, deposition, accumulation, or persistence of beta-amyloid containing plaques and tau protein containing tangles including the step of treating the plaques or tangles with an effective amount of a composition comprising anextract and an oolong tea extract. Compositions containing anextract in combination with an oolong tea extract.

Composition and methods for treating brain 'plaques' and 'tangles' in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprisingextract and an oolong tea extract.

Compositions and methods for the treatment of 'plaques and tangles' in humans and animals

Compounds and their pharmaceutically acceptable salts for treatment of tauopathies, such as Alzheimer's disease, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, familial frontotemporal dementia/Parkinsonism linked to chromosome 17, amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.

Compounds for the treatment of neurodegenerative diseases

Compounds and their pharmaceutically acceptable salts for treatment of &#x3b2;-amyloid diseases, such as observed in Alzheimer's disease and synucleinopathies, such as Parkinson's disease.

Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies

Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.

The identification of novel Syndecan-2 splice variants and their use in the diagnosis and therapeutic intervention of Alzheimer's disease and other amyloid diseases. In addition the use of new animal models expressing or devoid of syndecan-2 splice variants to effectively screen and identify potential therapeutic compounds for Alzheimer's disease.

Proteoglycan splice variants as therapeutics and diagnostics for amyloid diseases

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Compounds, compositions, and methods for the treatment of &#x3b2;-amyloid diseases and synucleinopathies

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of &#x3b2;-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies

A method of inhibiting the inflammatory process, the method comprising administering to a mammal suffering from inflammation a therapeutically effective amount of a pharmaceutical composition comprising a compound where:R is a C-Calkylene group, in which, when the number of carbon atoms is at least 2, there are optionally 1 or 2 non-adjacent double bonds; 1 to 3 non-adjacent methylene groups are optionally replaced by NR(where Ris H, alkyl, or acyl), O, or S; and 1 or 2 methylene groups are optionally replaced by a carbonyl or hydroxymethylene group and pharmaceutically acceptable esters or salts of the compounds and wherein the inflammatory process results from a disease selected from the group consisting of ulcerative colitis, endotoxic shock, rheumatoid arthritis, juvenile arthritis, osteoarthritis, psoriasis, Crohn's disease, inflammatory bowel disease, multiple sclerosis, insulin dependent diabetes mellitus, gout, psoriatic arthritis, reactive arthritis, vital or post-viral arthritis and ankylosing spondylarthritis.

Compounds, compositions and methods for the treatment of inflammatory diseases

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as Parkinson's disease, and the manufacture of medicaments for such treatment.

Growing community of inventors

Seattle, WA, United States of America

Joel Cummings